Core Viewpoint - Fuyuan Pharmaceutical's subsidiary has received approval for the production of a new oral solution, indicating a positive development in its product pipeline and potential revenue growth [2]. Group 1: Company Developments - Fuyuan Pharmaceutical announced that its wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for the oral solution of Ambroxol Hydrochloride (specification: 200ml: 160mg) [2]. - The approval of this drug is a significant milestone for the company, as it expands its product offerings in the pharmaceutical market [2]. Group 2: Industry Implications - The approval of new pharmaceutical products is crucial for companies in the industry, as it can lead to increased market share and revenue [2]. - This development reflects the ongoing regulatory support for new drug approvals, which is essential for innovation and competition within the pharmaceutical sector [2].

Core Viewpoint - Strongda Circuit has provided information regarding its PCB products, indicating a diverse range of offerings in the printed circuit board sector [2] Product Offerings - The company’s PCB products include single-sided and double-sided boards, high multilayer boards, high-frequency boards, high-speed boards, HDI boards, thick copper boards, rigid-flex boards, semiconductor test boards, and millimeter-wave radar boards [2]

证券日报网讯 2月10日，中国中铁在互动平台回答投资者提问时表示，作为基建行业国家队领军企业， 中国中铁始终将自身发展深度融入国家战略部署要求，紧密围绕国家扩内需等相关政策导向，统筹自身 资源优势，积极发挥应有作用。 （文章来源：证券日报） ...

Group 1 - The company, Conglin Technology, responded to investor inquiries on February 10, indicating that stakeholders should pay attention to the number of shareholders disclosed in the periodic reports [2]

（文章来源：证券日报） 证券日报网讯 2月10日，宋城演艺在互动平台回答投资者提问时表示，公司各期定期报告中已对政府补 助情况进行了相关披露，具体信息请查阅定期报告中的相关记载。 ...

Group 1 - The core point of the article is that Zhongshui Fisheries reported a total of 38,571 shareholders as of the end of January [2]

Group 1 - The company announced the resignation of Vice Chairman Yang Zhuang due to job adjustment reasons [2] - Yang Zhuang has applied to resign from multiple positions including Director, Vice Chairman, and Chairman of the Board's Editorial Committee [2] - The resignation was officially received by the company's board on February 10, 2026 [2]

证券日报网讯 2月10日，南极光在互动平台回答投资者提问时表示，公司严格遵守深交所规则履行信息 披露义务，具体信息请关注公司官方公告及定期报告。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月10日，中百集团在互动平台回答投资者提问时表示，公司根据自身经营发展实际、资 金安排等因素，在符合相关法律法规和《公司章程》规定的情况下回报投资者。 ...

Group 1 - The implementation of the "one certificate, one product" policy is beneficial for companies with rich registration resources, scale advantages, and strong brand influence [2] - The policy raises the entry barriers in the domestic formulation industry, which is expected to further enhance industry concentration in the future [2] - The company currently holds a total of 328 various pesticide certificates, including 50 active ingredient registration certificates and 278 formulation registration certificates, covering multiple product categories such as fungicides, insecticides, herbicides, soil conditioners, and seed coatings [2] - With a rich registration resource base, the company can provide a one-stop application solution across multiple categories, which is expected to enhance the market competitiveness of its domestic formulation products [2] - The company will leverage its existing advantages in active ingredient varieties and focus on the development and brand enhancement of formulation products, aiming to create new flagship products and further enhance its brand influence [2]